Lisata’s Marea Therapeutics Announces First Patient Dosed In Its Phase 2 Clinical Trial Of MAR002 For Treatment Of Acromegaly
Lisata Acquires Marea Therapeutics And Secures $225M Financing To Advance Next-Generation Medicines For Cardioendocrine Diseases
Nasdaq Edges Lower; Johnson & Johnson Earnings Top Estimates - Innovation Beverage Group (NASDAQ:IBG), Johnson & Johnson (NYSE:JNJ)
Dow Surges 300 Points; Netflix Shares Fall After Q4 Results - CN Energy Group (NASDAQ:CNEY), Innovation Beverage Group (NASDAQ:IBG)